Mabion S.A. (MAB.WA)
PLN 10.9
(-0.18%)
PLN 10.9
(-0.18%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 35.82 Million PLN | 392.14% |
| 2022 | 7.28 Million PLN | -64.25% |
| 2021 | 20.36 Million PLN | -44.48% |
| 2020 | 36.68 Million PLN | 67.19% |
| 2019 | 21.94 Million PLN | 289.21% |
| 2018 | 5.63 Million PLN | -91.46% |
| 2017 | 66.03 Million PLN | 419.11% |
| 2016 | 12.72 Million PLN | 5382.76% |
| 2015 | 232 Thousand PLN | 141.67% |
| 2014 | 96 Thousand PLN | 0.0% |
| 2013 | - PLN | 0.0% |
| 2012 | - PLN | 0.0% |
| 2011 | - PLN | 0.0% |
| 2010 | - PLN | 0.0% |
| 2009 | - PLN | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 24.13 Million PLN | -32.65% |
| 2024 Q3 | 1.86 Million PLN | -4.7% |
| 2024 Q2 | 3.91 Million PLN | -83.76% |
| 2023 Q4 | 35.82 Million PLN | -32.49% |
| 2023 Q3 | 53.06 Million PLN | 822.94% |
| 2023 FY | 35.82 Million PLN | 392.14% |
| 2023 Q1 | 6.84 Million PLN | -5.95% |
| 2023 Q2 | 5.75 Million PLN | -16.02% |
| 2022 FY | 7.28 Million PLN | -64.25% |
| 2022 Q4 | 7.28 Million PLN | -60.9% |
| 2022 Q3 | 18.61 Million PLN | -24.61% |
| 2022 Q2 | 24.69 Million PLN | 15.25% |
| 2022 Q1 | 21.42 Million PLN | 5.22% |
| 2021 Q4 | 20.36 Million PLN | 3.93% |
| 2021 Q3 | 19.59 Million PLN | -0.74% |
| 2021 Q2 | 19.74 Million PLN | -16.01% |
| 2021 FY | 20.36 Million PLN | -44.48% |
| 2021 Q1 | 23.5 Million PLN | -35.93% |
| 2020 Q1 | 21.36 Million PLN | -2.62% |
| 2020 FY | 36.68 Million PLN | 67.19% |
| 2020 Q2 | 21 Million PLN | -1.71% |
| 2020 Q3 | 26.55 Million PLN | 26.46% |
| 2020 Q4 | 36.68 Million PLN | 38.12% |
| 2019 Q3 | 5.42 Million PLN | -8.8% |
| 2019 Q4 | 21.94 Million PLN | 304.72% |
| 2019 Q2 | 5.94 Million PLN | 15.24% |
| 2019 Q1 | 5.15 Million PLN | -8.5% |
| 2019 FY | 21.94 Million PLN | 289.21% |
| 2018 Q3 | 5.67 Million PLN | -3.29% |
| 2018 FY | 5.63 Million PLN | -91.46% |
| 2018 Q4 | 5.63 Million PLN | -0.7% |
| 2018 Q2 | 5.87 Million PLN | -97.73% |
| 2018 Q1 | 258.44 Million PLN | 291.4% |
| 2017 FY | 66.03 Million PLN | 419.11% |
| 2017 Q1 | 26.2 Million PLN | 106.03% |
| 2017 Q2 | 54.73 Million PLN | 108.86% |
| 2017 Q3 | 53.77 Million PLN | -1.75% |
| 2017 Q4 | 66.03 Million PLN | 22.78% |
| 2016 FY | 12.72 Million PLN | 5382.76% |
| 2016 Q2 | 138 Thousand PLN | -10.97% |
| 2016 Q3 | 99 Thousand PLN | -28.26% |
| 2016 Q4 | 12.72 Million PLN | 12748.48% |
| 2016 Q1 | 155 Thousand PLN | -33.19% |
| 2015 FY | 232 Thousand PLN | 141.67% |
| 2015 Q4 | 232 Thousand PLN | 346.15% |
| 2015 Q3 | 52 Thousand PLN | -18.75% |
| 2015 Q2 | 64 Thousand PLN | 0.0% |
| 2015 Q1 | 64 Thousand PLN | -33.33% |
| 2014 FY | 96 Thousand PLN | 0.0% |
| 2014 Q4 | 96 Thousand PLN | 0.0% |
| 2014 Q2 | - PLN | 0.0% |
| 2014 Q1 | - PLN | 0.0% |
| 2014 Q3 | - PLN | 0.0% |
| 2013 Q1 | - PLN | 0.0% |
| 2013 Q2 | - PLN | 0.0% |
| 2013 Q3 | - PLN | 0.0% |
| 2013 Q4 | - PLN | 0.0% |
| 2013 FY | - PLN | 0.0% |
| 2012 Q4 | - PLN | 0.0% |
| 2012 FY | - PLN | 0.0% |
| 2012 Q3 | - PLN | 0.0% |
| 2011 FY | - PLN | 0.0% |
| 2010 FY | - PLN | 0.0% |
| 2009 FY | - PLN | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Bioceltix S.A. | 175.05 Thousand PLN | -20366.477% |
| BIOTON S.A. | 68.69 Million PLN | 47.843% |
| Captor Therapeutics Spolka Akcyjna | 3.77 Million PLN | -848.332% |
| Molecure S.A. | 7.13 Million PLN | -401.835% |
| NanoGroup S.A. | - PLN | -Infinity% |
| Pharmena S.A. | 181 Thousand PLN | -19694.475% |
| Poltreg S.A. | 8.19 Million PLN | -337.247% |
| Pure Biologics Spólka Akcyjna | 12.93 Million PLN | -176.921% |
| Ryvu Therapeutics S.A. | 906 Thousand PLN | -3854.525% |
| Synthaverse S.A. | 70.04 Million PLN | 48.848% |
| Urteste S.A. | 627 Thousand PLN | -5614.195% |